b7-h3 and its role in antitumor immunityb7-h3及其在抗肿瘤免疫作用.pdfVIP

Hindawi Publishing Corporation Clinical and Developmental Immunology Volume 2010, Article ID 683875, 7 pages doi:10.1155/2010/683875 Review Article B7-H3 and Its Role in Antitumor Immunity ¨ Martin Loos, Dennis M. Hedderich, Helmut Friess, and Jorg Kleeff Chirurgische Klinik und Poliklinik, Klinikum Rechts der Isar, Technische Universitat Munchen, Ismaninger Straße 22, ¨ ¨ 81675 Munchen, Germany ¨ ¨ Correspondence should be addressed to Jorg Kleeff, kleeff@chir.med.tu-muenchen.de Received 29 June 2010; Revised 16 September 2010; Accepted 19 October 2010 Academic Editor: C. D. Pauza Copyright © 2010 Martin Loos et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. B7-H3 is one of the most recently identified members of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T-cell response. Recently, B7-H3 expression has been reported in several human cancers indicating an additional function of B7-H3 as a regulator of antitumor immunity. However, its precise physiologic role is still elusive, because both stimulatory and inhibitory capacities have been demonstrated. This paper summarizes the available data on B7-H3 in the regulation of T-cell response focusing on its potential role in antitumor immunity. 1. Introduction ligand-1), B7-DC (programmed death-1 ligand-2), PD-